News

Discover how veteran finance executive Tim Gillespie, CFA, joins Biosenta as a strategic advisor to enhance their antimicrobial technology strategy.

Validated University of Calgary research demonstrates broad-spectrum efficacy of core-shell calcium hydroxide-calcium carbonate (CSCC(TM)) particles. Biosenta Inc. announced that two independent, peer-reviewed studies confirmed that its proprietary Tri-Filler™ nanoparticles achieved complete (100%) bactericidal activity against multiple World Health Organization (WHO) priority pathogens and keep working far longer than conventional biocides.

Biosenta announces significant advancements at its state-of-the-art bench scale production facility.

Biosenta granted to Lightweight Concrete Solutions a license to use Biosenta’s Tri-Filler® technology and get fee of C$200,000 and royalties

Biosenta has closed its private placement for gross proceeds of $600,000.

Biosenta announces a non-brokered private placement financing of up to $600,000.

Biosenta announces technological and operational advancements with successful construction and operation of a bench scale production plant.

Amarvir Gill, President, CEO and Director of Biosenta acquired 1,250,000 common shares and 625,000 warrants.

Biosenta announces that it has entered into debt settlement agreements with certain creditors.

Biosenta enters into debt settlement agreements with certain creditors.

Discover Biosenta's exciting engagement with Oak Hill Financial, offering insight into their business and capital markets advisory services.

Discover how Biosenta successfully closed a private placement financing of $500,000 for its future growth and development.

Biosenta announces a pivotal discovery revealed that Tri-Filler™ effectively sterilizes a wide range of microorganisms.

Biosenta will test Tri-Filler™ in plastics at AMPAK Inc. facilities with an eye to commercialization.

Biosenta Inc. announces further advances in research and development of the Tri-Filler™ particle.

Biosenta has completed termination of its joint venture agreement between the Company and 19443391 Ontario Inc and issued common shares.

Biosenta announces entering into of agreement to terminate joint venture

Biosenta Inc. announces that it has ceased negotiations with Voran Group Ventures Ltd.

Biosenta Inc. has signed an MOU with Voran Group Ventures Ltd. for the commercialization of Biosenta’s Tri-Filler® antimicrobial products.

Biosenta Inc. announced the annual general meeting of shareholders will take place on Tuesday, August 16, 2022, at 11:00am Eastern Time.